The CEO's sales are consistent with routine post-exercise liquidity and tax withholding, not a bearish signal. The EVP's sale is modest. Monitor next quarter's Tyvaso DPI growth trajectory and ralinepag NDA outcome for fundamental catalysts; insider activity alone does not warrant a trade.
Price Chart
Executive Summary
CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in open-market shares within two days of United Therapeutics' Q2 2026 earnings, which showed a 2% revenue miss and 4% decline in total Tyvaso sales. While the dollar amount is trivial relative to the $22.7B market cap (0.004%), the timing—immediately after a mixed earnings report—and the CEO's exercise of 9,500 options for cashless net-share settlement suggest the sales are primarily liquidity-driven rather than a bearish signal. The cluster is neutral: the CEO's sales follow a typical post-exercise pattern, and the EVP's sale is modest. No material directional read-through for the stock.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 632 shares at $539.14, 625 at $538.54, and 2,781 at $531.30 among 14 open-market sales on 2026-08-07, totaling ~$4.6M
- CEO also exercised 9,500 options at $0 (non-cash) and 9,500 options at $135.42 (cash exercise of $1.29M) on the same day
- EVP Paul Mahon sold 1,360 shares at $515.93 and 780 shares at $517.94 on 2026-08-06, totaling ~$1.1M
- Total open-market sales by both insiders: ~$5.7M, or 0.025% of $22.7B market cap
- Q2 2026 revenue of $783.3M missed consensus of $804.6M; diluted EPS of $7.27 beat $6.86 estimate
Financial Impact
Insider sales total ~$5.7M, immaterial relative to $22.7B market cap (0.025%)
Risk Factors
- Revenue miss in Q2 2026 driven by 4% Tyvaso decline may pressure near-term sentiment
- CEO's large option exercise and concurrent sales could be misinterpreted as insider pessimism
- No buys in the cluster—absence of insider buying post-earnings is a mild negative
- Pipeline catalysts (ralinepag, Tyvaso IPF) are binary events with regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786435291109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access